TARS (Tarsus Pharmaceuticals) FFO


TARS Tarsus Pharmaceuticals Inc TARS
48 GF Score
Price $67.11
GF Value $201.69
Valuation Possible Value Trap
! 2 Warning Signs
View Full Analysis

What is Tarsus Pharmaceuticals FFO?

FFO (Funds from operations) only applies to REITs.

TARS
48GF Score
Tarsus Pharmaceuticals Inc TARS
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Tarsus Pharmaceuticals (TARS) Overvalued in 2026?

Based on GuruFocus' analysis, Tarsus Pharmaceuticals stock appears to be undervalued. The current stock price of $67.11 is trading 66.7% below its estimated GF Value™ of $201.69. GuruFocus considers Tarsus Pharmaceuticals to be Possible Value Trap.

Key valuation signals for TARS:

  • FFO:
  • GF Value™: $201.69 vs. price of $67.11 (66.7% below fair value)
  • GF Score™: 48/100 with 2 warning signs

No single metric tells the full story. See the TARS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Tarsus Pharmaceuticals Business Description

Address 15440 Laguna Canyon Road, Suite 160, Irvine, CA, USA, 92618
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis. TP-04 for the potential treatment of ocular rosacea and TP-05 for potential Lyme disease prophylaxis and community malaria reduction.
48GF Score

Get the complete analysis for TARS

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$67.11
Price
$201.69
GF Value